Worldwide, hepatitis B virus is the major risk factor for hepatocellular carcinoma (HCC), owing to its high prevalence in the developing world. Hepatitis B virus vaccination programs have and will ...
Disparities in liver cancer risk and outcomes in the LGBTQ community: A literature review. Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A ...
Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback